Public Employees Retirement System of Ohio Purchases Shares of 26,103 Keros Therapeutics, Inc. $KROS

Key Points

• The Public Employees Retirement System of Ohio acquired 26,103 shares of Keros Therapeutics, Inc. for about $348,000, representing a 0.06% ownership at the end of the last quarter.
• Analyst ratings for Keros include a downgrade from Bank of America, reducing the price target from $32.00 to $18.00, while the average consensus target price currently stands at $30.00.
• Keros Therapeutics reported earnings of ($0.76) per share for the last quarter, outperforming expectations and showing a significant revenue increase of 49002.7% from the previous year.

Public Employees Retirement System of Ohio purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,103 shares of the company's stock, valued at approximately $348,000. Public Employees Retirement System of Ohio owned 0.06% of Keros Therapeutics at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of KROS. FNY Investment Advisers LLC acquired a new position in Keros Therapeutics in the first quarter valued at approximately $25,000. CWM LLC lifted its holdings in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after acquiring an additional 2,641 shares during the period. Entropy Technologies LP acquired a new position in Keros Therapeutics in the first quarter valued at approximately $121,000. AlphaQuest LLC lifted its holdings in Keros Therapeutics by 268.0% in the first quarter. AlphaQuest LLC now owns 13,234 shares of the company's stock valued at $135,000 after acquiring an additional 9,638 shares during the period. Finally, Corebridge Financial Inc. lifted its holdings in Keros Therapeutics by 6.4% in the first quarter. Corebridge Financial Inc. now owns 16,212 shares of the company's stock valued at $165,000 after acquiring an additional 972 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on KROS. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and decreased their price target for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. HC Wainwright decreased their price target on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Keros Therapeutics in a research report on Saturday, September 27th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $30.00.

Keros Therapeutics Stock Performance

Shares of KROS opened at $15.62 on Tuesday. The stock has a 50 day moving average price of $15.11 and a 200 day moving average price of $14.00. The stock has a market capitalization of $634.48 million, a price-to-earnings ratio of 50.39, a PEG ratio of 2.05 and a beta of 0.97. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm's revenue for the quarter was up 49002.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.25) earnings per share. On average, analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.